Downregulation of EYA2 leads to weak mesenchymal phenotypes, increased immunogenicity of cancer cells, reduced carcinogenicity, including tumor growth and metastasis, and increasing infiltration level of natural killer cells (NK cells) and cytotoxic T cells (97). This evidence concerns the gene EYA2 and cancer.